Last reviewed · How we verify

NCT03226600

OrACELL™ vs. Connective Tissue in Miller Class 3 Defects

Completed NA Last updated 24 July 2017
What this trial tests

NA trial testing OrACELL in Gingival Recession in 24 participants. Completed in 16 December 2016.

Timeline
26 March 2015
Primary endpoint
13 June 2016
16 December 2016

Quick facts

Lead sponsorTexas A&M University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment24
Start date26 March 2015
Primary completion13 June 2016
Estimated completion16 December 2016

Drugs / interventions tested

Conditions studied

Sponsor

Texas A&M University

Who can join

Adults 18 to 80, any sex, with Gingival Recession. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose was to compare root coverage outcomes between autogenous connective tissue graft (CTG) and decellularized human dermis (OrACELL™) in areas of facial gingival recession.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gingival Recession

Currently open trials in the same condition.

Other Texas A&M University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03226600.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing